Swiss drugmaker Roche to invest $50bn in US manufacturing amid tariff fears | Pharmaceuticals industry

Swiss drug maker Roch has announced that he will put 50 billion dollars (37 billion pounds) in manufacturing in the United States over the next five years, and join the waiting list of companies that reveal investments to try to leave Donald. Trump’s tariff.

Multinational drugs said on Tuesday that investment will create more than 12,000 new jobs, including 6500 construction jobs and 1,000 in new and expanded facilities in the United States, including factories and distribution centers in Kentucky, New Jersey and California.

Switzerland has a 10 % tariff, which is on the right path to rise to 31 % when the temporary suspension period ends for 90 days earlier this month.

However, the pharmaceutical industry is preparing for the definitions of the sector yet Trump announced a 21 -day achievement last week under the Trade Expansion LawIt is widely considered the first step towards fees on imports.

Roche, which includes well -known drugs to treat Herceptin Hylecta, OCREVUS multiple sclerosis and major drugs for arthritis, HIV and HIV, employ about 25,000 locations in the United States.

As soon as new and expanded facilities are operated, Roche will export more drugs from the United States than currently imported.

She said that a new genetic treatment factory will be built in Pennsylvania, along with a new plant to monitor the continuous glucose in Indiana.

In addition, you will build a new factory for losing weight loss with the site that has not yet been announced, along with a cardiovascular studies and metabolic research center in Massachusetts.

“Our investments amounting to 50 billion dollars over the next five years will establish our next era of innovation and growth, as it has benefited from patients in the United States and around the world,” CEO, Thomas Xinker, said in a statement.

When Trump announced the pharmaceutical trade investigation last Tuesday, he also launched an investigation into semiconductors, the fourth of five sectors, the Trump administration said was a strategic mission for the United States.

It has already announced a tariff for sectoral imports, cars, steel and aluminum, with the fifth sector, wood and copper, which is already under investigation under Article 232 of the Commercial Expansion Law.

Europe, India and China are seen as especially vulnerable to pharmaceutical tariffs given its huge exports. Trump has repeatedly delegated Ireland with the alleged theft of American industry, with US multinational companies including Johnson & Johnson, Elie Lily and Bozer, all of whom have been working there for decades.

Another Swiss drug maker, Novartis, said earlier this month that he would spend $ 23 billion in the United States, while Johnson & Johnson said in March that it would invest $ 55 billion in manufacturing, research and development, including a factory in North Carolina. Elie Lily said in February that it would put $ 27 billion in four new factories.

They hope the investments will be sufficient to reduce the Trump tariff, with European drug heads warning this month “Exit” investment From Europe.